Abu Dhabi, June 16, 2022 (WAM)-Emirate Health Regulatory Authority-Abu Dhabi (DoH) Declares Cooperation with Johnson & Johnson Middle East FZ-LLC to Support Abu Dhabi’s Vision Signed in the development of a regional hub for clinical research and data generation.

The new strategic collaboration aims to bring innovative therapies and breakthrough solutions to the UAE and MENA regions, exchanging knowledge and experience throughout the healthcare sector.

The signing ceremony witnessed by Abu Dhabi Ministry of Health (DoH) President Abdullah bin Mohammed al-Hamed took place June 13-16 at the BIO International Convention 2022 in San Diego, California, USA.

The Collaboration Declaration was signed by Dr. Asma Armanney, Executive Director of DoH’s Research and Innovation Center, and Jamie Farres, Managing Director of Janssen GCC, one of Johnson & Johnson’s pharmaceutical companies.

Abu Dhabi’s delegation is attending the BIO International Conference 2022 to showcase the domestic growth and economic development of Abu Dhabi’s biotechnology industry. A delegation of Abu Dhabi, headed by high-ranking government officials led by Abdullah bin Mohammed al-Hamed, chair of the Ministry of Health of Abu Dhabi (DoH), visited the United States this month for a particularly large life sciences.

Through these strategic collaborations, DoH, Johnson & Johnson Middle East, FZ LLC has key potential interests in developing short-term and long-term projects in the generation of data and real-world evidence (RWE). Explore the field. Through international cooperation, Abu Dhabi aims to lead a research group supported by global partners, establish strengths and sustainability in the healthcare sector, and provide quality care to patients.

Dr. Asma Al Mannaei, Executive Director of the Research Innovation Center of the Ministry of Health of Abu Dhabi (DoH), said: As an innovation incubator. Through collaboration with Johnson Middle East, FZ LLC, he aims not only to provide quality care to patients in Abu Dhabi and around the world, but also to further improve the resilience and sustainability of the healthcare sector. .. ”

Leveraging a strong infrastructure and advanced healthcare ecosystem, opportunities for collaboration across Abu Dhabi’s biopharmacy and healthcare value chains continue to emerge due to the strong growth potential of the sector. .. Through international collaboration, Abu Dhabi aims to lead a research group backed by global partners to explore the resilience and sustainability of the healthcare sector around the world and to provide quality care to patients. ..

Source link

Previous articleGame tax hikes “question” investors-analysts
Next articleFood bite, latest Macan news